PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 48 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 2.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $352,601 | -23.7% | 34,002 | +5.3% | 0.00% | – |
| Q2 2023 | $462,308 | +1552.6% | 32,276 | +723.8% | 0.00% | – |
| Q1 2023 | $27,975 | -66.4% | 3,918 | -47.2% | 0.00% | – |
| Q4 2022 | $83,264 | +1.5% | 7,421 | 0.0% | 0.00% | – |
| Q3 2022 | $82,000 | +51.9% | 7,421 | +17.3% | 0.00% | – |
| Q2 2022 | $54,000 | -25.0% | 6,328 | +20.1% | 0.00% | – |
| Q1 2022 | $72,000 | -29.4% | 5,267 | +1.7% | 0.00% | – |
| Q4 2021 | $102,000 | -38.9% | 5,178 | 0.0% | 0.00% | – |
| Q3 2021 | $167,000 | +103.7% | 5,178 | +112.3% | 0.00% | – |
| Q2 2021 | $82,000 | +41.4% | 2,439 | +57.3% | 0.00% | – |
| Q1 2021 | $58,000 | +7.4% | 1,551 | -4.4% | 0.00% | – |
| Q4 2020 | $54,000 | +10.2% | 1,623 | +22.7% | 0.00% | – |
| Q3 2020 | $49,000 | -18.3% | 1,323 | -27.0% | 0.00% | – |
| Q2 2020 | $60,000 | +42.9% | 1,812 | +12.1% | 0.00% | – |
| Q1 2020 | $42,000 | -36.4% | 1,616 | -23.7% | 0.00% | – |
| Q4 2019 | $66,000 | – | 2,117 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 4,901,358 | $41,368,000 | 8.59% |
| Frazier Life Sciences Management, L.P. | 5,827,415 | $49,183,000 | 4.64% |
| Abingworth LLP | 1,435,106 | $12,112,000 | 3.88% |
| Penn Mutual Asset Management | 86,940 | $734,000 | 0.99% |
| 683 Capital Management, LLC | 1,440,000 | $12,153,000 | 0.86% |
| Western Standard LLC | 109,055 | $920,000 | 0.70% |
| MPM BioImpact LLC | 193,326 | $1,632,000 | 0.45% |
| Newtyn Management, LLC | 255,767 | $2,159,000 | 0.41% |
| StepStone Group LP | 422,085 | $3,562,000 | 0.38% |
| Avidity Partners Management LP | 1,919,800 | $16,203,000 | 0.37% |